ClinicalTrials.gg
Drug

Izalontamab brengitecan clinical trials

Also written BL-B01D1 and BMS-986507.

studies test it
58
open now
46
in phase 3
25
first study started
2021

How each study uses izalontamab brengitecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the izalontamab brengitecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

iza-bren
54
izalontamab brengitecan
54

Development codes

BL-B01D1
55
BMS-986507
54

Studies by the year they started

58 studies that test it; most in 2026 (16)

Studies that test izalontamab brengitecan, by start year
YearStudies
20211
20223
202311
202414
202513
202616

Who runs them

Industry 55 · Other 3

Sichuan Baili Pharmaceutical Co., Ltd. (49) · Bristol-Myers Squibb (5) · Fudan University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · SystImmune Inc. (1) · Sichuan University (1)

Often tested with

Tested in the same studies.

Immune checkpoint inhibitors (7) · Danvilostomig (7) · Docetaxel (3) · Gemcitabine (3) · Capecitabine (3) · Eribulin (2) · Vinorelbine (2) · Irinotecan (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 31, 5 in phase 3

Studies that test izalontamab brengitecan, phase 3 first.

Studies

Open first, then newest update. How each study uses izalontamab brengitecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 58

See all 58 studies that test izalontamab brengitecan →

Given beside what is tested · 2 — izalontamab brengitecan is usual care or a partner of the new treatment

Codes

What other systems call izalontamab brengitecan · ClinicalTrials.gg INT018114

  • UNII (FDA) UC2FX6YY3PIZALONTAMAB BRENGITECANOne source FDA
  • NCI Thesaurus C203048Izalontamab BrengitecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.